NCT04767321 - A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

March 23, 2021

Study Completion Date

June 1, 2021

Conditions

Nasal Decolonization of Staphylococcus Aureus

Interventions

DRUG

LTX-109 gel, 3% w/w

LTX-109 gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.

DRUG

Placebo

Placebo gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.

Trial Locations (1)

SE-752 37

ClinSmart Sweden AB, Uppsala